BioFocus and Ono Sign a Drug Discovery Agreement
News Sep 03, 2012
Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed.
“We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client” said Dr. Chris Newton, SVP Galapagos Services and Managing Director of BioFocus. “This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.”
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “We have the highest regard for the BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”
Stereochemistry is a science of reflection. Two chemical molecules with the same composition and structure, but with one as the mirror image of the other, can produce wildly varying effects. But University of Utah chemist Matt Sigman has been developing a way to get a better grasp on this tricky field of chemistry.READ MORE